The Cost‑Effectiveness and Cost‑Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease, A Systematic Review

Mahmoud Eisavi, Elaheh Mazaheri, Aziz Rezapour, Sajad Vahedi, Marziye Hadian, Abdosaleh Jafari


Cardiovascular diseases impose a burden of disease and economic burden on society. With regard to different drugs are used to treat cardiovascular disease; these interventions should be economically evaluated and them that the most cost‑effective were selected. The aim of this study was to investigate the studies carried on the cost‑effectiveness and cost‑utility of statin drugs for the treatment of patients with cardiovascular disease between 2004 and 2020. Quality assessment of the articles was examined by Drummond’s checklist. Given that the inclusion criteria, 26 articles included in the review. The results of this review showed that many articles related to the economic evaluation of statin drugs adhered international standards for performing economic evaluation studies. All the studies mentioned the source of effectiveness (the second criteria) and alternative options for the comparison (the third criteria). Atorvastatin and rosuvastatin drugs were the main options for the comparison in the studies. Although the results of the studies were different in some aspects, such as the type of modeling, costs items and the study perspective, they reached the same results which the use of statin drugs versus no‑drug can decrease cost, cardiovascular events and deaths and increase QALY. The results were nearly different due to study design, time horizon, efficacy, and drug prices.


Cost‑benefit analysis; cardiovascular diseases; statin drugs; systematic review

Full Text:



Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA,

Naghavi M, et al. Global and regional patterns in cardiovascular

mortality from 1990 to 2013. Circulation 2015;132:1667‑78.

Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K,

et al. Reducing the global burden of cardiovascular disease,

part 1: The epidemiology and risk factors. Circulation Res


Gupta S, Epari V, Bhatia S. Potential gains of screening family

members of suspected coronary artery disease: A pilot study. Int

J Prev Med 2019;10:148.

Javadi M, Jamalzehi A, Gerami H, Hosseini SK, Maljaei MB,

Eslami M, et al. Association between dietary intakes of

tea, coffee, and soft drinks in patients undergoing coronary

angiography with coronary artery stenosis. Int J Prev Med


World Health Organization. Cardiovascular diseases (CVDs).

Fact Sheet 2016(317).

Roth GA, Johnson C, Abajobir A, Abd‑Allah F, Abera SF,

Abyu G, et al. Global, regional, and national burden of

cardiovascular diseases for 10 causes, 1990 to 2015. J Am

College Cardiol 2017;70:1‑25.

Forouzanfar MH, Sepanlou SG, Shahraz S, BESc PN,

Pourmalek F, Lozano R, et al. Evaluating causes of death and

morbidity in Iran, global burden of diseases, injuries, and risk

factors study 2010. Arch Iran Med 2014;17:304.

Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The

annual global economic burden of heart failure. Int J Cardiol


Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden

from non‑communicable diseases in low‑ and middle‑income

countries: A literature review. Health Res Policy Syst 2013;11:31.

Yusefi AR, Lankarani KB, Bastani P, Radinmanesh M, Kavosi Z.

Risk factors for gastric cancer: A systematic review. Asian Pac J

Cancer Prev 2018;19:591‑603.

Leong DP, Joseph PG, McKee M, Anand SS, Teo KK,

Schwalm JD, et al. Reducing the global burden of cardiovascular

disease, part 2: Prevention and treatment of cardiovascular

disease. Circ Res 2017;121:695‑710.

Collins M, Mason H, O’Flaherty M, Guzman‑Castillo M,

Critchley J, Capewell S. An economic evaluation of salt

reduction policies to reduce coronary heart disease in England:

A policy modeling study. Value Health 2014;17:517‑24.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,

Ioannidis JP, et al. The PRISMA statement for reporting

systematic reviews and meta‑analyses of studies that evaluate

health care interventions: Explanation and elaboration. J Clin

Epidemiol 2009;62:e1‑34.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL,

Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; 2015.

Aarnio E, Korhonen MJ, Huupponen R, Martikainen J.

Cost‑effectiveness of statin treatment for primary prevention in

conditions of real‑world adherence–estimates from the Finnish

prescription register. Atherosclerosis 2015;239:240‑7.

Rezapour A, Hadian M, Ghasemi M, Vahedi S, Jafari A.

Economic Evaluation of the Drugs Used In Treating Patients

with Myocardial Infarction: A Systematic Review. Journal of

Health Management & Informatics. 2019;6:7-14.

Agus A, Hulme C, Verghis R, McDowell C, Jackson C,

O’Kane C, et al. Simvastatin for patients with acute respiratory

distress syndrome: Long‑term outcomes and cost‑effectiveness

from a randomised controlled trial. Critical Care 2017;21:108.

Amirsadri M, Hassani A. Cost‑effectiveness and cost‑utility

analysis of OTC use of simvastatin 10 mg for the primary

prevention of myocardial infarction in Iranian men. Daru


Ara R, Pandor A, Stevens J, Rafia R, Ward S, Rees A, et al.

Prescribing high‑dose lipid‑lowering therapy early to avoid

subsequent cardiovascular events: Is this a cost‑effective

strategy? Eur J Prev Cardiol 2012;19:474‑83.

Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R,

et al. Estimating the health benefits and costs associated with

ezetimibe coadministered with statin therapy compared with

higher dose statin monotherapy in patients with established

cardiovascular disease: Results of a Markov model for UK costs

using data registries. Clin Ther 2008;30:1508‑23.

Jabbari A, Jafari A, Hadian M, Ghasemi M. Model-based Costeffectiveness Analysis of Atorvastatin Drugs for Prevention of

Cardiovascular Diseases in Iran. Int J Prev Med. 2020;11:57.

Barrios V, Lobos JM, Serrano A, Brosa M, Capel M,

Álvarez Sanz C. Cost‑effectiveness analysis of rosuvastatin vs

generic atorvastatin in Spain. J Med Econ 2012;15(Sup 1):45‑54.

Burgers L, Nauta S, Deckers J, Severens J, Redekop WK. Is

it cost‑effective to use a test to decide which individuals with

an intermediate cardiovascular disease risk would benefit from

statin treatment? Int J Cardiol 2014;176:980‑7.

Fragoulakis V, Kourlaba G, Maniadakis N. Economic evaluation

of statins in high‑risk patients treated for primary and secondary

prevention of cardiovascular disease in Greece. Clinicoecon

Outcomes Res 2012;4:135‑43.

Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG,

Paulsson TJC, et al. Cost‑effectiveness of rosuvastatin in

comparison with generic atorvastatin and simvastatin in a

Swedish population at high risk of cardiovascular events.

Clinicoecon Outcomes Res 2012;4:1‑11.

Grabner M, Winegar DA, Punekar RS, Quimbo RA, Cziraky MJ,

Cromwell WC. Cost effectiveness of achieving targets of

low‑density lipoprotein particle number versus low‑density

lipoprotein cholesterol level. Am J Cardiol 2017;119:404‑9.

Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L,

Odden MC, et al. Evaluating the impact and cost‑effectiveness

of statin use guidelines for primary prevention of coronary heart

disease and stroke. Circulation 2017;136:1087‑98.

Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A,

Fialkow JA, et al. Implications of coronary artery calcium

testing for treatment decisions among statin candidates

according to the ACC/AHA cholesterol management guidelines:

A cost‑effectiveness analysis. JACC Cardiovasc Imaging


Jeong Y, Kim H, Baik S, Kim T, Yang S, Lee SH, et al. Analysis and comparison of the cost‑effectiveness of statins according to the baseline low‑density lipoprotein cholesterol level in Korea. J Clin Pharm Ther 2017;42:292‑300.

Lin F‑J, Shyu K‑G, Hsieh I‑C, Sheu WH‑H, Tu S‑T,

Yeh S‑J, et al. Cost‑effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL‑C 70–100 mg/dL in Taiwan. J Formos Med Assoc 2020;119:907‑16.

Lum CJ, Nakagawa K, Shohet RV, Seto TB, Taira DA. The

cost‑benefit balance of statins in Hawai‘i: A moving target.

Hawaii J Med Public Health 2017;76:99‑102.

Mullins CD, Rattinger GB, Kuznik A, Koren MJ.

Cost‑effectiveness of intensive atorvastatin treatment in high‑risk patients compared with usual care in a postgeneric statin market: Economic analysis of the aggressive lipid‑lowering initiation abates new cardiac events (ALLIANCE) study. Clin Ther


Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA.

Cost‑effectiveness of 10‑year risk thresholds for initiation of

statin therapy for primary prevention of cardiovascular disease.

JAMA 2015;314:142‑50.

Pandya A, Weinstein MC, Salomon JA, Cutler D, Gaziano TA.

Who needs laboratories and who needs statins?: Comparative

and cost‑effectiveness analyses of non–laboratory‑based,

laboratory‑based, and staged primary cardiovascular disease

screening guidelines. Circ Cardiovasc Qual Outcomes


Pinto CG, Carrageta MO, Miguel LS. Cost‑effectiveness of

rosuvastatin in the prevention of ischemic heart disease in

Portugal. Value Health 2008;11:154‑9.

Reckless J, Davies G, Tunceli K, Hu XH, Brudi PJ. Projected

cost‑effectiveness of ezetimibe/simvastatin compared with

doubling the statin dose in the United Kingdom: Findings from

the INFORCE study. Value Health 2010;13:726‑34.

Ribeiro RA, Duncan BB, Ziegelmann PK, Stella SF,

Vieira JLdC, Restelatto LMF, et al. Cost‑effectiveness of high,

moderate and low‑dose statins in the prevention of vascular

events in the Brazilian public health system. Arq Bras Cardiol


Stam‑Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA,

Visseren FL. Cost‑effectiveness of intensifying lipid‑lowering

therapy with statins based on individual absolute benefit

in coronary artery disease patients. J Am Heart Assoc


Stomberg C, Albaugh M, Shiffman S, Sood N.

A cost‑effectiveness analysis of over‑the‑counter statins. Am J

Manag Care 2016;22:e294‑303.

Vegter S, Oosterhof P, van Boven JF, Stuurman‑Bieze AG,

Hiddink EG, Postma MJ. Improving adherence to lipid‑lowering

therapy in a community pharmacy intervention program:

A cost‑effectiveness analysis. J Manag Care Spec Pharm


Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: An audit of NICE current practice and a review of its use and value in decision‑making. Health Technol Assess; 2009;13:iii.

Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing

structural uncertainty in decision analytic models: A review and

application of methods. Value Health 2009;12:739‑49